Related Experiment Videos
Peripheral arterial occlusive disease: conservative treatment of intermittent claudication
1Department of Cardiology and Angiology, School of Medicine, University of Tübingen, Esslingen, F.R.G.
Insights
Oral drug therapy can significantly increase pain-free walking distance for peripheral arterial occlusive disease patients with intermittent claudication within 3-6 months, offering an alternative when other treatments are not feasible.
Area of Science:
- Vascular Medicine
- Pharmacology
- Clinical Therapeutics
Background:
- Intermittent claudication is a primary symptom of stage II peripheral arterial occlusive disease (PAOD).
- PAOD is a manifestation of systemic atherosclerosis requiring management of underlying risk factors.
- Treatment strategies must address both the systemic disease and the symptom of claudication.
Purpose of the Study:
- To evaluate the efficacy of oral drug therapy for improving intermittent claudication.
- To determine if pharmacological interventions offer a statistically significant benefit over placebo.
Main Methods:
- Systematic review and meta-analysis of eight controlled, randomized studies.
- Comparison of oral drug administration versus placebo.
- Assessment of pain-free walking distance as the primary outcome measure.
Main Results:
- Oral drug administration resulted in a statistically significant increase in pain-free walking distance compared to placebo.
- Benefits were observed within 3-6 months of treatment initiation.
- Drug therapy demonstrated efficacy in improving a key symptom of PAOD.
Conclusions:
- Oral drug therapy is an effective treatment option for patients experiencing intermittent claudication.
- This therapeutic approach should be considered for patients unsuitable for revascularization, angioplasty, or walking training.
- Pharmacological management offers a viable strategy to improve quality of life in PAOD patients.
Abstract:
Intermittent claudication is the principal symptom in stage II of peripheral arterial occlusive disease. As this is a multilocular manifestation of atherosclerosis, a distinction must be drawn between treatment of the underlying disease with consideration of the individual risk factors and improvement and abolition of the intermittent claudication. Various therapeutic principles exist, and drug therapy is the subject of controversial discussion. On the basis of eight controlled, randomized studies, it was demonstrated that in comparison with placebo a statistically significant increase in the pain-free walking distance can be achieved by oral drug administration within 3-6 months. This drug therapy should be considered for those patients with intermittent claudication who cannot undergo revascularization, angioplasty, or walking training.